Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”

Chief Business Officer Neela Patel, Ph.D., will discuss the promise and challenges of these next-generation drugs, which have the potential to overcome shortcomings of current state-of-the-art therapies, including ADCs and bispecifics…

We are delighted to welcome Sam Blackman to the Bonum Therapeutics team. His judgment and his deep experience in the clinical development of novel immune-oncology agents will benefit…

“We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program…”